Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.32 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.32 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14432237 | 0.87 | CD44 (0.38) | CD44CYP3A4GRIN2DGRIN3BGRIN1 | |
| SCHEMBL944491 | 0.85 | CD44 (0.37) | CD44CYP3A4GRIN2DGRIN3BGRIN1 | |
| SCHEMBL946586 | 0.84 | CD44 (0.33) | CD44CYP3A4 | |
| SCHEMBL13191797 | 0.83 | CD44 (0.35) | CD44CYP3A4GRIN2DGRIN3BGRIN1 | |
| SCHEMBL5485596 | 0.81 | MAPK1 (0.35) | CYP3A4 | |
| SCHEMBL12811480 | 0.75 | GRIN2D (0.47) | CD44CYP3A4GRIN2DGRIN3BGRIN1 | |
| SCHEMBL195131 | 0.75 | CD44 (0.42) | CD44CYP3A4GRIN2DGRIN3BGRIN1 | |
| SCHEMBL22295234 | 0.74 | CD44 (0.38) | CD44CYP3A4GRIN2DGRIN3BGRIN1 | |
| SCHEMBL17466153 | 0.73 | CD44 (0.41) | CD44CYP3A4GRIN2DGRIN3BGRIN1 | |
| SCHEMBL17466157 | 0.73 | CD44 (0.41) | CD44CYP3A4GRIN2DGRIN3BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875753-B2 | formed by reacting aryldiazonium bromide with vinylidene chloride in presence of copper salt and bromide source | BAYER CROPSCIENCE AG (DE) | 2011-01-25 | — | — | US | disclosed |
| US-7875753-B2 | formed by reacting aryldiazonium bromide with vinylidene chloride in presence of copper salt and bromide source | BAYER CROPSCIENCE AG (DE) | 2011-01-25 | — | — | US | disclosed |
| US-7875753-B2 | formed by reacting aryldiazonium bromide with vinylidene chloride in presence of copper salt and bromide source | BAYER CROPSCIENCE AG (DE) | 2011-01-25 | — | — | US | disclosed |
| WO-2010105739-A1 | AROMATIC 2-BROMO-2,2-DICHLOROETHYL COMPOUNDS AND METHODS FOR THE PRODUCTION THEREOF | BAYER CROPSCIENCE AG (DE) | 2010-09-23 | — | — | WO | disclosed |
| WO-2010105739-A1 | AROMATIC 2-BROMO-2,2-DICHLOROETHYL COMPOUNDS AND METHODS FOR THE PRODUCTION THEREOF | BAYER CROPSCIENCE AG (DE) | 2010-09-23 | — | — | WO | disclosed |
| US-20100234651-A1 | 2-Bromo-2,2-Dichloroethyl Aromatics and Process for Preparation Thereof | BAYER CROPSCIENCE AG (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234651-A1 | 2-Bromo-2,2-Dichloroethyl Aromatics and Process for Preparation Thereof | BAYER CROPSCIENCE AG (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100234651-A1 | 2-Bromo-2,2-Dichloroethyl Aromatics and Process for Preparation Thereof | BAYER CROPSCIENCE AG (DE) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234651-A1 | 2-Bromo-2,2-Dichloroethyl Aromatics and Process for Preparation Thereof | AR, AHR, ADRA2C | CD44 4648/4885CYP3A4 40/4885GRIN2D 2707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.